Project Grant HT9425261E270

Federal Project Grant Award Summary The National Cancer Institute awarded the University of Pittsburgh a $1.3 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through May 31, 2030, to develop highly tumor-selective pan RAS inactivators for targeting oncogenic RAS-driven cancers. The project addresses a critical unmet medical need by engineering a novel therapeutic approach that combines the anthrax toxin protein delivery system with DUF5...

Federal Grant Award Summary New York University School of Medicine received a $435,827 Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) effective June 4, 2025, with completion targeted for May 31, 2027. The grant supports research entitled "Exploiting Synthetic Lethality to Enhance KRAS Inhibitor Therapy of Cancer," which investigates combination therapeutic strategies to overcome intrinsic and emergent resistance to...

Federal Grant Award Summary The National Cancer Institute (NCI) awarded Columbia University's Health Sciences Division a $682,673 Project Grant under the Cancer Treatment Research program (CFDA 93.395) for research on "Adaptation and Evolution of Resistance to Pan-RAS Inhibition in Pancreatic Ductal Adenocarcinoma." The five-year project, spanning May 1, 2026 through April 30, 2031, supports fundamental and applied research investigating mechanisms of tumor resistance to pan-RAS...

Summary Oregon Health & Science University received a $625,179 Project Grant award on March 26, 2026, from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to develop and validate targeted therapies for osteosarcoma lung metastasis. The research will deliver comprehensive preclinical evaluation and development of MCL1 (myeloid cell leukemia-1) inhibitors, both as standalone treatments and in combination with chemotherapy, using innovative...

Federal Grant Award Summary The National Cancer Institute (NCI) awarded a five-year Project Grant totaling $675,009 to the University of California, San Francisco (UCSF) beginning August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395). This grant supports the development of covalent inhibitors targeting RAS Q61 mutations, which occur in approximately 90% of RAS Q61-mutant cancers including hematologic malignancies, melanoma, thyroid cancer, and pediatric cancers. The research,...

Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $375,150 to The Regents of the University of California, San Francisco under the Cancer Treatment Research program (CFDA 93.395) to fund a five-year research initiative (September 1, 2025 – August 31, 2030). The research addresses innate resistance mechanisms to KRAS inhibitors in cancer treatment, focusing on the role of the RhoA-ROCK-Myosin IIA cytoskeletal axis in promoting drug-tolerant persister...

This federal Project Grant award from the Department of Health and Human Services National Institutes of Health National Cancer Institute, under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $613,054 to St. Jude Children's Research Hospital Inc. to study the mechanisms by which transcription factors control different cell states in neuroblastoma, a high-risk pediatric tumor. The key objectives are to 1) interrogate how master transcription factors control the...

Federal Grant Award Summary St. Jude Children's Research Hospital Inc. received a $475,681 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) for the period June 12, 2026 through May 31, 2028. The award supports research exploring CDC2-like kinase 2 (CLK2) as a novel therapeutic target in rhabdomyosarcoma (RMS), the most common soft tissue sarcoma in children and young adults. Given the critical clinical need—five-year event-free...

Federal Grant Award Summary The National Cancer Institute (NCI) awarded Children's Research Institute $467,968 through the Cancer Treatment Research program (CFDA 93.395) for a Project Grant effective June 1, 2026, through May 31, 2028. The research evaluates the synergistic therapeutic effects of retinoic acid (RA) combined with proteasome inhibitors (bortezomib, carfilzomib, and ixazomib) as a novel treatment strategy for high-risk neuroblastoma, a common pediatric solid tumor with poor...

Federal Grant Award Summary The National Cancer Institute awarded Seattle Children's Hospital (doing business as Seattle Children's Research Institute) a $3.48 million Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective August 1, 2025, through July 31, 2029. This project systematically identifies genomic heterogeneity and relapse predictors in pediatric and adolescent/young adult patients with Philadelphia chromosome-positive (PH+) and ABL-class PH-like acute...